Arcadia Biosciences, Inc. (RKDA) shareholders
Close on Nov 17, 2026Market cap $457.03KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| MJL Manager LLC Joint filing with Michael Liu (15.70%), Capuchin Capital Fund LP (15.70%) | 378,740 | 15.70% | 13G (passive) | Sep 25, 2026 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 267,392 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Steven Boyd Joint filing with Armistice Capital, LLC (7.75%) | 159,390 | 7.75% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RKDA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hrt Financial LP | 88,386 | 3.67% | $60.00K | New | 0.00% |
| Citadel Advisors LLC | 23,738 | 0.99% | $16.12K | New | 0.00% |
| Virtu Financial LLC | 21,786 | 0.90% | $15.00K | New | 0.00% |
| Geode Capital Management, LLC | 16,135 | 0.67% | $10.96K | −15,608 | 0.00% |
| XTX Topco Ltd | 15,475 | 0.64% | $10.51K | New | 0.00% |
| StoneX Group Inc. | 13,682 | 0.57% | $11.26K | New | 0.00% |
| State Street Corp | 12,146 | 0.50% | $8.25K | – | 0.00% |
| Jane Street Group, LLC | 10,245 | 0.43% | $6.96K | New | 0.00% |
| Vanguard Capital Management LLC | 9,644 | 0.40% | $6.55K | – | 0.00% |
| SBI Securities Co., Ltd. | 120 | 0.00% | $81 | – | 0.00% |
| TD Waterhouse Canada Inc. | 70 | 0.00% | $50 | New | 0.00% |
| UBS Group AG | 35 | 0.00% | $24 | −772 | 0.00% |
| Group One Trading, L.P. | 18 | 0.00% | $12 | – | 0.00% |
| Morgan Stanley | 2 | 0.00% | $1 | – | 0.00% |
| Southern Michigan Bank & Trust | 2 | 0.00% | $1 | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | 0.00% | $1 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 16 | 0M | 8.8% | 8 / 0 | 2 / 7 | 0M | 0M |
| Q1 2026 | 15 | 0M | 14.5% | 6 / 3 | 0 / 3 | 0M | 0M |
| Q4 2025 | 13 | 0M | 1.6% | 0 / 0 | 6 / 3 | 0M | 0M |
| Q3 2025 | 16 | 0M | 2.7% | 3 / 2 | 5 / 1 | 0M | 0M |
| Q2 2025 | 14 | 0M | 2.5% | 1 / 3 | 2 / 1 | 0M | 0M |
| Q1 2025 | 14 | 0M | 3.2% | 2 / 3 | 1 / 1 | 0M | 0M |
| Q4 2024 | 13 | 0M | 3.3% | 3 / 1 | 0 / 3 | 0M | 0M |
| Q3 2024 | 13 | 0M | 2.2% | 3 / 0 | 2 / 1 | 0M | 0M |
| Q2 2024 | 11 | 0M | 1.2% | 2 / 0 | 2 / 4 | 0M | 0M |
| Q1 2024 | 13 | 0M | 3.4% | 2 / 2 | 1 / 3 | 0M | 0M |
| Q4 2023 | 14 | 0M | 5.8% | 3 / 4 | 0 / 0 | 0M | 0M |
| Q3 2023 | 11 | 0M | 2.0% | 0 / 1 | 5 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held RKDA in Q2 2026, 24% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RKDA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 27,879 | 1.16% | $26.90K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 9,644 | 0.40% | $6.55K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 1,716 | 0.07% | $1.66K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 1,626 | 0.07% | $1.57K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas J. Schaefer | Chief Executive Officer | 2,819 | 0.12% | May 12, 2025 |
| Mark Kawakami | Chief Financial Officer | 2,681 | 0.11% | May 12, 2025 |
| Lilian Shackelford Murray | Director | 8,524 | 0.35% | Sep 14, 2026 |
| Kevin Comcowich | Director | 20,000 | 0.83% | Sep 14, 2026 |
| Gregory D. Waller | Director | – | – | Sep 14, 2026 |
| Amy Yoder | Director | – | – | Sep 14, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark Kawakami Chief Financial Officer | Feb 3, 2025 | Buy | +700 | $2.49 | $1.74K | 2,681 |
| Thomas J. Schaefer Chief Executive Officer | Feb 3, 2025 | Buy | +700 | $2.49 | $1.74K | 2,819 |
| Mark Kawakami Chief Financial Officer | Aug 1, 2024 | Buy | +700 | $2.06 | $1.44K | 1,981 |
| Thomas J. Schaefer Chief Executive Officer | Aug 1, 2024 | Buy | +700 | $2.06 | $1.44K | 2,119 |
| Thomas J. Schaefer Chief Financial Officer | Feb 1, 2024 | Buy | +700 | $2.06 | $1.44K | 1,419 |
| Thomas J. Schaefer Chief Financial Officer | Aug 4, 2023 | Buy | +649 | $3.67 | $2.38K | 719 |
| Stanley Jacot Jr Chief Executive Officer | May 30, 2023 | Buy | +5,000 | $4.31 | $21.55K | 5,000 |
| Thomas J. Schaefer Chief Financial Officer | Feb 1, 2023 | Buy | +700 | $0.23 | $161 | 2,800 |
| Pamela Haley Chief Financial Officer | Aug 1, 2022 | Buy | +700 | $0.70 | $490 | 5,088 |
| Randall Shultz Chief Technology Officer | Aug 3, 2020 | Buy | +700 | $3.16 | $2.21K | 13,000 |
| Pamela Haley Chief Financial Officer | Aug 3, 2020 | Buy | +700 | $3.16 | $2.21K | 2,638 |
| Matthew T. Plavan Chief Executive Officer | Aug 3, 2020 | Buy | +585 | $3.16 | $1.85K | 14,285 |
| Sarah Reiter Chief Commercial Officer | Feb 3, 2020 | Buy | +700 | $1.72 | $1.20K | 3,800 |
| Matthew T. Plavan Chief Executive Officer | Feb 3, 2020 | Buy | +700 | $1.72 | $1.20K | 13,700 |
| Pamela Haley Chief Financial Officer | Feb 3, 2020 | Buy | +700 | $1.72 | $1.20K | 1,938 |
| Sarah Reiter Chief Commercial Officer | Dec 23, 2019 | Buy | +900 | $5.95 | $5.36K | 3,100 |
| Sarah Reiter Chief Commercial Officer | Nov 19, 2019 | Buy | +1,000 | $4.52 | $4.52K | 2,200 |
| Lilian Shackelford Murray Director | Nov 18, 2019 | Buy | +5,000 | $4.25 | $21.25K | 8,524 |
| Matthew T. Plavan Chief Executive Officer | Nov 14, 2019 | Buy | +1,000 | $4.08 | $4.08K | 13,000 |
| Matthew T. Plavan Chief Executive Officer | Sep 23, 2019 | Buy | +2,000 | $5.25 | $10.50K | 12,000 |
| Kevin Comcowich Director | Sep 17, 2019 | Buy | +5,000 | $5.88 | $29.40K | 20,000 |
| Matthew T. Plavan Chief Executive Officer | Sep 10, 2019 | Buy | +1,000 | $6.52 | $6.52K | 10,000 |
| Matthew T. Plavan Chief Executive Officer | Sep 10, 2019 | Buy | +1,000 | $6.49 | $6.49K | 9,000 |
| Sarah Reiter Chief Commercial Officer | Sep 10, 2019 | Buy | +1,200 | $6.48 | $7.78K | 1,200 |
| Kevin Comcowich Director | Sep 10, 2019 | Buy | +5,000 | $6.49 | $32.45K | 5,000 |
| Kevin Comcowich Director | Sep 10, 2019 | Buy | +10,000 | $6.49 | $64.90K | 15,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 28, 2019 | Award | +1,000 | $6.88 | $6.88K | 8,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 28, 2019 | Buy | +1,000 | $6.88 | $6.88K | 8,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Award | +2,000 | $8.93 | $17.86K | 7,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Award | +1,000 | $9.32 | $9.32K | 3,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Award | +1,000 | $9.30 | $9.30K | 4,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Award | +1,000 | $8.95 | $8.95K | 5,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Buy | +1,000 | $8.95 | $8.95K | 5,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Buy | +1,000 | $9.32 | $9.32K | 3,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Buy | +1,000 | $9.30 | $9.30K | 4,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 27, 2019 | Buy | +2,000 | $8.93 | $17.86K | 7,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 26, 2019 | Award | +1,000 | $8.33 | $8.33K | 1,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 26, 2019 | Award | +1,000 | $9.22 | $9.22K | 2,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 26, 2019 | Buy | +1,000 | $8.33 | $8.33K | 1,000 |
| Matthew T. Plavan Chief Financial Officer | Aug 26, 2019 | Buy | +1,000 | $9.22 | $9.22K | 2,000 |
| Eric J. Rey Director | Mar 23, 2018 | Option exercise | +5,000 | $21.60 | $108.00K | 12,335 |
| Eric J. Rey Director | Mar 23, 2018 | Sale | −5,000 | $33.44 | $167.20K | 7,335 |
| Zhongjin Lu VP Product Development | Mar 23, 2018 | Sale | −1,750 | $32.74 | $57.30K | 558 |
| Zhongjin Lu VP Product Development | Mar 23, 2018 | Option exercise | +1,750 | $21.60 | $37.80K | 2,308 |
| Eric J. Rey Director | Mar 15, 2018 | Option exercise | +250 | $44.80 | $11.20K | 7,585 |
| Eric J. Rey Director | Mar 15, 2018 | Sale(10b5-1 plan) | −250 | $60.00 | $15.00K | 7,335 |
| Eric J. Rey Director | Mar 14, 2018 | Sale(10b5-1 plan) | −21,005 | $45.21 | $949.64K | 7,335 |
| Eric J. Rey Director | Mar 14, 2018 | Option exercise | +21,005 | $21.60 | $453.71K | 28,340 |
| Zhongjin Lu VP Product Development | Nov 17, 2017 | Sale | −5,950 | $0.23 | $1.37K | 11,153 |
| Eric J. Rey Director | Jun 8, 2017 | Buy | +5,000 | $0.75 | $3.75K | 146,680 |
| Roger Salameh Chief Operating Officer | Aug 4, 2016 | Sale(10b5-1 plan) | −100 | $2.51 | $251 | 11,415 |
| Roger Salameh Chief Operating Officer | Aug 4, 2016 | Option exercise | +100 | $1.08 | $108 | 11,515 |
| Steven F. Brandwein Interim Chief Financ. Officer | Jun 13, 2016 | Sale(10b5-1 plan) | −8,280 | $2.49 | $20.62K | 750 |
| Steven F. Brandwein Interim Chief Financ. Officer | Apr 25, 2016 | Sale(10b5-1 plan) | −1,720 | $2.42 | $4.16K | 9,030 |
| Vic C. Knauf Chief Scientific Officer, Director | Apr 5, 2016 | Sale(10b5-1 plan) | −1,653 | $2.98 | $4.93K | 47,134 |
| Vic C. Knauf Chief Scientific Officer, Director | Apr 5, 2016 | Option exercise | +1,653 | $1.08 | $1.79K | 48,787 |
| Vic C. Knauf Chief Scientific Officer, Director | Apr 4, 2016 | Option exercise | +1,200 | $1.08 | $1.30K | 48,334 |
| Vic C. Knauf Chief Scientific Officer, Director | Apr 4, 2016 | Sale(10b5-1 plan) | −1,200 | $2.98 | $3.58K | 47,134 |
| Vic C. Knauf Chief Scientific Officer, Director | Mar 4, 2016 | Option exercise | +2,973 | $1.08 | $3.21K | 50,107 |
| Vic C. Knauf Chief Scientific Officer, Director | Mar 4, 2016 | Sale(10b5-1 plan) | −2,973 | $3.22 | $9.57K | 47,134 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Arcadia Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 840,555 shares on Oct 14, 2026 over the last 90 days.
See a number that looks wrong?